CAS 27378-49-0 Poly-L-ornithine solution - Analytical Products / Alfa Chemistry

CAT	AP27378490-B
CAS	27378-49-0
Structure
MDL Number	MFCD00286305

Description	mol wt 30,000-70,000, 0.01%, sterile-filtered, BioReagent, suitable for cell culture
Form	solution
Impurity Content	endotoxin, tested
Size	50ML
Storage Conditions	2-8°C

Conformational Properties of poly-L-ornithine in Aqueous Solution

G Conio, E Patrone, A Tealdi, E Bianchi

Ric Sci. 1969 Jan;39(1):61-7.

PMID: 5362112

Formation and Spectral Characterization of Cu(II)-poly(L-ornithine) Complexes

C V Phan, L Tosi, A Garnier

Bioinorg Chem. 1978;8(1):21-31.

PMID: 23868

Helix-coil Transition of poly-L-ornithine in Solution

S R Chaudhuri, J T Yang

Biochemistry. 1968 Apr;7(4):1379-83.

PMID: 5677828

Interaction of Sodium Decyl Sulfate With poly(L-ornithine) and poly(L-lysine) in Aqueous Solution

I Satake, J T Yang

Biopolymers. 1976 Nov;15(11):2263-75.

PMID: 990408

Preparation and Evaluation of PEGylated Poly-L-ornithine Complex as a Novel Absorption Enhancer

Yusuke Kamiya, Tsutomu Yamaki, Masaki Uchida, Tomomi Hatanaka, Mitsutoshi Kimura, Masahiko Ogihara, Yasunori Morimoto, Hideshi Natsume

Biol Pharm Bull. 2017;40(2):205-211.

PMID: 28154261

* Products or Services Interested: Poly-L-ornithine solution (27378-49-0)
* Your question
* Name
* Email
Verification Code

Case Study

Poly-L-ornithine (PLO) for the Preparation of Microcapsules

Xue, Wen, et al.Acta Biomaterialia 138 (2022): 182-192.

and cellular scaffolds. However, due to their weak physical cross-linking properties, PECs can expand, leading to the burst release of encapsulated substances. To overcome these drawbacks, alginate (Alg)/poly-L-ornithine (PLO) PEC hydrogels were developed into microcapsules, fibers, and bulk scaffolds to explore their feasibility as drug and cell carriers.
Preparation of Alg/PLO Microcapsules
The microcapsules were prepared using a wholly aqueous electrospraying technique. In short, PLO (Mw = 30,000-70,000 Da) dissolved in 0.15 M phosphate-buffered saline (PBS, pH = 7.5) was used as the droplet phase, while PBS-dissolved Alg with a concentration range of 0.1%-1% (w/v) served as the continuous phase, unless otherwise specified. The PLO solution was loaded into a syringe equipped with a 22 G metal needle, connected to the cathode of a power supply. The Alg solution was stirred at 50 rpm and placed 5 cm below the needle tip, grounded. Under the applied electrical field, micron-size PLO droplets were drawn from the needle and collected in the Alg bath. The applied voltage was 8 kV, with a PLO solution flow rate of 1 mL/h.

Poly-L-ornithine Significantly Enhances the Proliferation of Neural Stem/Progenitor Cells

Ge, H., Tan, L., Wu, P., Yin, Y., Liu, X., Meng, H., ... & Feng, H. (2015). Scientific reports, 5(1), 15535.

Neural stem/progenitor cells (NSPCs) were cultured following well-established standard protocols in an enriched medium containing 20 ng/ml bFGF and 20 ng/ml EGF. Firstly, a CCK8 assay indicated that NSPCs grown on Poly-L-ornithine (PO) exhibited higher absorbance at 450 nm on both the 7th and 14th days compared to those grown on Poly-L-lysine (PLL) or Fibronectin (FN), suggesting that NSPCs proliferated more robustly on PO. Secondly, Ki-67 staining results showed that the percentage of Ki-67 and Nestin co-labeling was significantly higher in NSPCs cultured on PO than in those cultured on PLL or FN on both the 7th and 14th days. Thirdly, Western blot data revealed that the expression levels of Nestin, a marker preferentially expressed in NSPCs, were significantly higher in NSPCs grown on PO compared to those grown on PLL or FN on both the 7th and 14th days. These data indicate that PO has a superior capability to promote NSPC proliferation compared to PLL or FN.

Preparation of Poly(L-lactic-co-glycolic) Acid (PLGA)-(Poly-L-ornithine (PLO)/Fucoidan)₄

Fan, Jingqian, et al. RSC advances 7.52 (2017): 32786-32794.

In the Layer-by-Layer (LbL) nanoparticles (NPs), a nanocore of drug-loaded poly(L-lactic-co-glycolic) acid (PLGA) is alternately coated with layers of poly-L-ornithine (PLO) and the sulfated polysaccharide, fucoidan, to form a composite shell. Following the encapsulation of the anti-cancer drug doxorubicin (DOX) into the PLGA core, an enhanced drug encapsulation efficiency was observed. The in vitro release studies of these LbL NPs demonstrated the effective exploitation of this core-shell structure to accommodate and control the release of the drug payload.
Preparation of PLGA-(PLO/Fucoidan)₄ NPs (LbL NPs)
The PLO and fucoidan polymers are alternately self-assembled into layers with a polyelectrolyte concentration of 1 mg/mL. To prepare the polyelectrolyte multilayer films, 10 mg of PLGA NPs or DOX-loaded PLGA NPs (DOX-PLGA NPs) were sequentially added to 10 mL of each polyelectrolyte solution via static adsorption. After each polyelectrolyte addition, excess solution was rinsed away with water. This process was repeated multiple times to construct the PLGA-(PLO/Fucoidan)₄ NPs. Samples were designated as PLGA-(PLO/Fucoidan)_0.5 NPs, PLGA-(PLO/Fucoidan)₁ NPs, PLGA-(PLO/Fucoidan)_1.5 NPs, etc., based on the number of layers applied. Similarly, DOX-loaded PLGA NPs (DOX-PLGA NPs) were prepared following the same procedure to obtain multilayered polymer coatings.

Poly-L-ornithine solution

Poly-L-ornithine (PLO) for the Preparation of Microcapsules

Poly-L-ornithine Significantly Enhances the Proliferation of Neural Stem/Progenitor Cells

Preparation of Poly(L-lactic-co-glycolic) Acid (PLGA)-(Poly-L-ornithine (PLO)/Fucoidan)4

Preparation of Poly(L-lactic-co-glycolic) Acid (PLGA)-(Poly-L-ornithine (PLO)/Fucoidan)₄